Novo Nordisk

News

Novo Nordisk cuts $1.3bn deal for KBP blood pressure drug

Novo Nordisk has agreed a $1.3 billion deal with Singapore’s KBP Biosciences to buy ocedurenone, a drug for uncontrolled hypertension that ties in with its ongoing efforts

News

Novo Nordisk’s semaglutide aces another outcomes trial

Novo Nordisk has halted a phase 3 trial of its Ozempic formulation of GLP-1 agonist semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD) early aft

News

Valo Health bags $2.7bn AI partnership with Novo Nordisk

Novo Nordisk has paid $60 million to partner Valo Health on a project that will apply the US start-up’s artificial intelligence-powered drug discovery engine to find new t

News

Wegovy finally reaches the UK, in 'limited' quantities

Novo Nordisk's sought-after obesity therapy Wegovy has finally reached the UK and can be prescribed by NHS weight management services – but supplies are being carefully co

News

Novo Nordisk buys another obesity biotech

Novo Nordisk has agreed its second acquisition in the space of a month of a biotech in the obesity category, snapping up fellow Danish company Embark Biotech for €15 milli

News